This trial is enrolling individuals with chronic (1-10 years) and subacute (20-90 days) cervical spinal cord injury to test the safety and effect of an experimental drug, NVG-291. Enrollment of the chronic group has been completed, approximately 20 individuals will be enrolled in the subacute group. If included, participants will receive a daily subcutaneous (under the skin) injection for 12 weeks of either: 1) NVG-291; or 2) a placebo drug. In lab studies, NVG-291 improved locomotion and bladder recovery. Final testing of central nervous system conduction (electrophysiology) as well as upper and lower limb function will be assessed after 16 weeks.
Traumatic
Type
Details
- participants will receive a daily subcutaneous (under the skin) injection of either 1) NVG-291 or 2) a placebo drug for the first 12 weeks of the study. - Final testing of upper and lower limb function will be assessed after 16 weeks.
Main benefits
Standing/walking/mobility
Additional benefits
Arm/hand function
General health
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more